155 related articles for article (PubMed ID: 29505523)
1. Aberrations and clinical significance of BRAF in malignant melanoma: A series of 60 cases in Chinese Uyghur.
Kang X; Zeng Y; Liang J; Li J; Ren D; Chai L; Sun Z; Yu S; Wu X; Han W; Wang W
Medicine (Baltimore); 2018 Jan; 97(1):e9509. PubMed ID: 29505523
[TBL] [Abstract][Full Text] [Related]
2. Analysis of KIT mutations and c-KIT expression in Chinese Uyghur and Han patients with melanoma.
Kang XJ; Shi XH; Chen WJ; Pu XM; Sun ZZ; Halifu Y; Wu XJ; Yu SR; Liu WX; Liang JQ; Luo D; Ren DY
Clin Exp Dermatol; 2016 Jan; 41(1):81-7. PubMed ID: 25917463
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.
Si L; Kong Y; Xu X; Flaherty KT; Sheng X; Cui C; Chi Z; Li S; Mao L; Guo J
Eur J Cancer; 2012 Jan; 48(1):94-100. PubMed ID: 21788131
[TBL] [Abstract][Full Text] [Related]
4. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.
Hay R; MacRae E; Barber D; Khalil M; Demetrick DJ
Arch Pathol Lab Med; 2007 Sep; 131(9):1361-7. PubMed ID: 17824790
[TBL] [Abstract][Full Text] [Related]
7. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
8. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
9. Characterizations of Gene Alterations in Melanoma Patients from Chinese Population.
Luo Y; Zhang Z; Liu J; Li L; Xu X; Yao X; Dai Z; Wang X; Yang S; Wu H; Bu J; Wu Y; Xiang T; Li X
Biomed Res Int; 2020; 2020():6096814. PubMed ID: 32083130
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan.
Sheen YS; Liao YH; Liau JY; Lin MH; Hsieh YC; Jee SH; Chu CY
J Formos Med Assoc; 2016 Feb; 115(2):121-7. PubMed ID: 25767048
[TBL] [Abstract][Full Text] [Related]
11. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
13. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
14. BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han.
Qi RQ; He L; Zheng S; Hong Y; Ma L; Zhang S; Zhao L; Guo X; Wang Y; Yu JY; Fu L; Zhang W; Long T; Zhang C; Chen G; Lin J; Wang C; Zhou L; Mi Q; Weiland M; Chen JZ; McHenga SS; Wang YK; McHepange U; Wang Z; Chen HD; Gao XH
J Invest Dermatol; 2011 May; 131(5):1129-38. PubMed ID: 21326296
[TBL] [Abstract][Full Text] [Related]
15. Mutational profiling of acral melanomas in Korean populations.
Shim JH; Shin HT; Park J; Park JH; Lee JH; Yang JM; Kim DH; Jang KT; Lee DY
Exp Dermatol; 2017 Oct; 26(10):883-888. PubMed ID: 28191690
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
17. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
18. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
19. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma.
Kim SY; Kim SN; Hahn HJ; Lee YW; Choe YB; Ahn KJ
J Am Acad Dermatol; 2015 Jun; 72(6):1036-46.e2. PubMed ID: 25819940
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin.
Uribe P; Wistuba II; González S
Am J Dermatopathol; 2003 Oct; 25(5):365-70. PubMed ID: 14501284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]